The burgeoning landscape of medication for obesity and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant differences in their pharmacological profiles and clinical study results are emerging. Retatrutide, b… Read More

Arriving in the landscape of weight management treatment, retatrutide represents a distinct approach. Different from many existing medications, retatrutide works as a twin agonist, at once affecting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. This dual stimulation promotes multiple beneficial effe… Read More